

Follow these steps to submit prior authorization requests when prescribing drugs covered under the medical benefit for Blue Cross Blue Shield of Michigan and Blue Care Network commercial members.

Michigan prescribers

To submit prior authorization requests electronically, first register for Availity® Essentials, our provider portal; refer to the [Register for web tools](#) page at bcbsm.com for details. Then:

1. Log in to [availity.com](#)*.
2. Click *Payer Spaces* on the menu bar and click the BCBSM and BCN logo.
3. On the Applications tab, click the tile for the appropriate NovoLogix web tool.
4. Within NovoLogix, click the *Authorizations* menu and select *Create Authorization*.
5. Enter the member's details and select the correct member on the contract.
6. Complete the required fields. This includes selecting the correct drug in the "Authorization Lines" section.
7. Click *Submit*, complete the protocol questions and click *Done*.

If you're registered for Availity but are not able to access it, submit your prior authorization request using the *Medication Authorization Request Form*, or MARF, that's on the next page.

Non-Michigan prescribers

When submitting a prior authorization request for the first time, prescribers located outside of Michigan should complete and submit:

- The *Medication Authorization Request Form*, or MARF, that's on the next page
- The [Application for access to NovoLogix for non-Michigan prescribers](#)

Submit these documents to the fax number or address that's on the MARF. Once we approve the request for access, we'll provide information about how to access the NovoLogix tool so that you can submit subsequent prior authorization requests electronically.

Note: Access to NovoLogix is available only to registered users. You must include a valid Type 1 (individual) NPI on the application for access to NovoLogix.

Information about NovoLogix

For more information about the NovoLogix web tool, look under the Training Resources heading on these webpages:

- [Blue Cross Medical-Benefit Drugs](#)
- [BCN Medical-Benefit Drugs](#)

If you need help with the NovoLogix tool, contact the Web Support Help Desk at 1-877-258-3932.

*Clicking this link means that you're leaving the Blue Cross Blue Shield of Michigan and Blue Care Network website. While we recommend this site, we're not responsible for its content.

Availity® is an independent company that contracts with Blue Cross Blue Shield of Michigan and Blue Care Network to offer provider portal services.

Authorization Request Form

Amvuttra™ (vutrisiran) HCPCS CODE: J0225

This form is to be used by participating physicians to obtain coverage for Amvuttra™. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION		PHYSICIAN INFORMATION	
Name		Name	
ID Number		Specialty	
D.O.B. <input type="checkbox"/> Male <input type="checkbox"/> Female		Address	
Diagnosis		City /State/Zip	
Drug Name <input type="checkbox"/> Amvuttra™		Phone/Fax: P: () - F: () -	
Dose and Quantity Weight (kg)		NPI	
Directions		Contact Person	
Date of Service(s)		Contact Person Phone / Ext.	

STEP 1: DISEASE STATE INFORMATION

- Is this request for: ☐ Initiation ☐ Continuation Date patient started therapy: _____
- Please provide the NPI number for the place of administration: _____
- Initiation AND Continuation of therapy:**
 - Does the patient have peripheral neuropathy caused by hereditary transthyretin amyloidosis (hATTR) with a documented TTR mutation? ☐ Yes ☐ No Comment _____
 - Please check off the symptoms of neuropathy the patient is experiencing: ☐ Tingling/pain in the hands/feet/arms
☐ Numbness/tingling in the wrists ☐ Carpal tunnel syndrome ☐ Loss of ability to sense temperature
☐ Weakness in legs/difficulty walking ☐ Difficulty with fine motor skills ☐ Orthostasis ☐ Abnormal sweating
☐ Constipation/diarrhea ☐ Nausea/vomiting ☐ Anorexia/early satiety ☐ Loss of feeling in the hand and/or feet
☐ Other: _____
 - Does the patient have any signs or symptoms of ocular amyloidosis or primary/leptomeningeal amyloidosis? ☐ Yes ☐ No
 - If Yes, do these predominate over polyneuropathy symptomology?
☐ Yes ☐ No Comment _____
 - What is the patient's PND score before starting Amvuttra? ☐ 0 ☐ I ☐ II ☐ IIIA ☐ IIIB ☐ IV
 - What is the patient's FAP stage before starting Amvuttra? ☐ 0 ☐ 1 ☐ 2 ☐ 3
 - Will the patient be using Amvuttra in combination with other therapies approved for transthyretin-mediated amyloidosis?
☐ Yes ☐ No Comment _____
 - Has the patient had a prior liver transplant? ☐ Yes ☐ No
 - Does the patient have heart failure? ☐ Yes ☐ No If Yes: New York Heart Association Class ☐ I ☐ II ☐ III ☐ IV
- Continuation of therapy:**
 - Has the patient's condition improved while on therapy with Amvuttra?
☐ Yes ☐ No Comment _____

Please add any other supporting medical information necessary for our review

Coverage will not be provided if the prescribing physician's signature and date are not reflected on this document.

☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function

Physician's Name	Physician Signature	Date
Step 2: Checklist <input type="checkbox"/> Form Completely Filled Out <input type="checkbox"/> Attached Chart Notes		
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320

Confidentiality notice: This transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of this document is strictly prohibited. If you have received this in error, please notify the sender to arrange for the return of this document.

8/4/2022; 10/5/2022